Sign In
Buy OKYO
$1.66
-0.0400 (-2.35%)
At Close: Jun 03, 2026
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
09:21am, Wednesday, 16'th Jul 2025
LONDON and NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic cornea
OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts
02:00pm, Wednesday, 11'th Jun 2025
Shares of OKYO Pharma Ltd (NASDAQ:OKYO) have nearly doubled since the start of the year, fueled by a string of clinical and regulatory milestones that may pave the way for a transformative treatment
Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited
10:05am, Wednesday, 11'th Jun 2025
Raising Price Target Due to Fundamental Drivers BALTIMORE, MD / ACCESS Newswire / June 11, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap se
OKYO Pharma CEO to present drug research for debilitating eye pain at Boston summit
09:35am, Monday, 19'th May 2025
OKYO Pharma Ltd (NASDAQ:OKYO) shares could see renewed attention this week as the company's chief executive, Gary Jacob, is set to present findings on its lead drug candidate at a biotech conference i
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
07:00am, Monday, 19'th May 2025
LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic co
OKYO moves toward FDA talks after eye drug trial – ICYMI
05:18pm, Friday, 02'nd May 2025
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the early termination of its Phase 2 trial evaluating urcosimod (formerly OK-101) for neuropathic corneal pain. The company said the 48-patien
OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal pain
08:36am, Thursday, 01'st May 2025
OKYO Pharma Ltd (NASDAQ:OKYO) announced that the US Food and Drug Administration has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP), a chronic ocular
OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal pain
10:02am, Wednesday, 30'th Apr 2025
OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to accelerate the clinical development of urcosimod, formerly called OK-101, to treat neuropathic corneal pain. The company has chosen to end its Phas
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
07:00am, Wednesday, 30'th Apr 2025
LONDON and NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) t
OKYO Pharma CEO discusses FDA Fast Track filing for urcosimod - ICYMI
09:08am, Saturday, 05'th Apr 2025
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the company's recent developments, including the formal naming of its drug candidate OK-101 as urcosimod. Jacob discussed the c
OKYO Pharma reports long-term shelf stability of corneal pain treatment
08:49am, Monday, 31'st Mar 2025
OKYO Pharma Ltd (NASDAQ:OKYO) said on Monday that its experimental drug urcosimod has demonstrated stability for over two and a half years in single-use ampoules. The biopharmaceutical company's confi
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
08:00am, Monday, 31'st Mar 2025
LONDON and NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic
OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatment
09:09am, Monday, 10'th Mar 2025
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has filed a Fast Track designation application with the US Food and Drug Administration (FDA) for urcosimod, for the treatment of neuropathic corneal pa
OKYO Pharma secures USAN designation ‘urcosimod' for lead asset
09:10am, Wednesday, 12'th Feb 2025
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its lead asset, OK-101, has been granted the United States Adopted Name (USAN) "urcosimod." The company said the designation reinforces its progress in dev
OKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believe
12:46pm, Friday, 31'st Jan 2025
OKYO Pharma Ltd (NASDAQ:OKYO) is uniquely positioned to emerge as a key player in the ocular treatment arena as it advances its lead therapeutic candidate OK-101, analysts at Goldman Small Cap Researc
